What is Conagen?
Conagen is a distinguished biotechnology company situated in the prominent Boston biotech corridor. The company specializes in the innovation and development of synthetic biology solutions, providing critical support to global partners across a wide array of current and emerging markets. Conagen's expertise spans proprietary strain development, advanced fermentation processes, and scaling up production. This comprehensive capability enables its partners to effectively market and sell products in sectors including food, nutrition, flavor and fragrance, pharmaceuticals, and renewable materials.
How much funding has Conagen raised?
Conagen has raised a total of $32.3M across 3 funding rounds:
Corporate Investment
$30M
Debt
$1M
Debt
$1.3M
Corporate Investment (2020): $30M with participation from Sumitomo Chemical
Debt (2020): $1M led by PPP
Debt (2021): $1.3M supported by PPP
Key Investors in Conagen
Sumitomo Chemical
Sumitomo Chemical is a major player in the chemical industry, likely investing in Conagen to leverage synthetic biology for advancements in materials science and sustainable solutions.
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Conagen?
The recent major strategic investment positions Conagen for accelerated growth and expanded market penetration. With a strong foundation in synthetic biology and a proven track record of scaling production, the company is poised to further solidify its impact across the food, nutrition, flavor and fragrance, pharmaceutical, and renewable materials industries. This strategic backing will likely fuel further research and development, enabling Conagen to introduce novel solutions and enhance its offerings to a global clientele, reinforcing its status as a key player in the biotechnology sector.
See full Conagen company page
